| Data suggest that phosphatase of regenerating liver-3 (PRL-3)might play a tumor suppressor role in lung cancer, distinct from other cancers, by inhibiting epithelial-mesenchymal transition (EMT)-related pathways. | liver,lung, |
| miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. | gastric, |
| our findings suggest that miR-495 and miR-551a both act as tumor suppressors by targeting the PRL-3 oncogene and inhibiting gastric cancer cell migration and invasion. | gastric, |
| miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer. | colorectal,liver, |
| The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia. | leukemia, |
| PTP4A3 may play a role in bladder cancer oncogenesis and is a predictive marker of metastasis. PTP4A3 overexpression represents an independent prognosticator for BC, suggesting its potential theranostic value. | bladder, |
| PRL-3 exerts oncogenic functions in myeloid leukemia cells via aberrant dephosphorylation of stathmin and activation of STAT3 signaling. | leukemia, |
| These results demonstrate that FKBP38 is a novel regulator of the oncogenic protein PRL-3 abundance and that alteration in the stability of PRL-3 can have a dramatic impact on cell proliferation. | None |
| Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice. | None |
| Molecular mechanisms of the PRL phosphatases. | None |
| Studies indicate that PRL-1 and PRL-2 and PRL-3 are oncogenes and belong to the few phosphatases that lead to the development of cancer. | None |